Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28563410 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL21939748 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL10089216 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4122754 | 0.85 | HTT (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL21553751 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL24183536 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL30380328 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL25904933 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL460173 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL15140566 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377748-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2017093208-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377748-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | SMN1; SMN2 4557/4885NPC1 447/4885RAB9A 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.